Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
- MindBio kiosks use artificial intelligence and voice analysis to detect potential intoxication and fatigue in workplace environments.
- The company is targeting industries such as mining, aviation, construction, transportation, and law enforcement, where safety-sensitive operations require large-scale screening.
- MindBio’s AI models have been trained on more than 50 million data points and analyze over 140 acoustic markers associated with impairment.
- Prototype kiosks are entering testing, validation, and data-analysis phases, before broader commercial deployment.
- The company is positioning this important new technology as a faster and less invasive alternative to traditional drug and alcohol testing methods.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, has reached a new development milestone with the completion and delivery of its first prototype Edge AI Intoxication and Fatigue Detection Kiosks, advancing the company’s effort to commercialize voice-based impairment detection technology for workplace safety applications. According to a recent company announcement, the kiosks combine proprietary hardware and software designed to assess intoxication and fatigue through short voice samples analyzed by artificial intelligence (https://ibn.fm/cnaJn).
The prototypes have now entered a testing and validation phase that will involve collaboration with industry participants, speech specialists and software engineers. The objective is to refine the company’s predictive models and evaluate performance under real-world operating conditions before broader commercial deployment.
The launch comes as employers across multiple industries face increasing pressure to improve workplace safety while managing the costs and operational burdens associated with conventional drug and alcohol testing programs.
Traditional screening methods, including breathalyzers, saliva tests, urine analysis and laboratory testing, remain widely used but often require significant administrative resources, trained personnel and processing time. For large employers operating in safety-sensitive sectors, testing hundreds or even thousands of workers can create logistical challenges.
MindBio is pursuing a different approach. Rather than relying on biological samples, the company’s technology analyzes vocal characteristics that may change when an individual is impaired by alcohol, drugs or fatigue. According to the company, its artificial intelligence platform evaluates more than 140 acoustic markers and has been trained using a dataset exceeding 50 million data points collected through years of research.
The result is intended to be a rapid screening process that can be completed through a standard microphone, potentially reducing the need for more invasive testing while enabling organizations to screen large workforces efficiently.
MindBio’s initial commercialization efforts are focused on industries where impairment management is already a regulatory and operational priority. Mining operations represent a particularly attractive market. Many mines operate around the clock, employ large workforces and often function in remote environments where safety protocols are critical. Conducting traditional drug and alcohol testing at scale can be both costly and time consuming.
The company has also identified aviation, construction, heavy transportation and law enforcement as target sectors. These industries share a common need for rapid, scalable and repeatable screening processes that can help identify individuals who may require additional evaluation.
MindBio recently expanded its platform beyond intoxication detection with the addition of fatigue recognition capabilities, reflecting growing industry interest in managing fatigue-related workplace risks alongside substance impairment.
The kiosk deployment follows several recent developments within MindBio’s commercialization strategy. Earlier this month, the company announced the launch of Intox AI(TM), its lead enterprise software platform designed to detect alcohol intoxication, drug use and fatigue through voice analysis. The platform is intended to serve as the analytical engine behind future kiosk deployments and enterprise integrations.
MindBio has also filed patent applications covering aspects of its AI-powered voice analysis technology, reflecting management’s effort to build an intellectual property portfolio around the platform as commercialization advances.
The company is entering a market that continues to expand as employers adopt new safety technologies and regulators place greater emphasis on workplace compliance. Demand for impairment detection tools is being driven by industries where employees operate heavy machinery, manage transportation systems or perform other safety-critical tasks. Organizations are increasingly seeking solutions that can improve efficiency while maintaining testing standards.
MindBio’s strategy centers on providing a scalable screening layer that can be deployed at facility entrances, worksites and operational checkpoints. Workers provide a short voice sample, and the system generates an assessment within seconds. Those flagged for potential impairment can then undergo additional evaluation using existing testing protocols.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
